KI-Beratung Beta

Produktbild: Cancer Drug Design and Discovery

Cancer Drug Design and Discovery

124,99 €

inkl. gesetzl. MwSt., Versandkostenfrei


Beschreibung

Cancer Drug Design and Discovery, Second Edition is an important reference on the underlying principles for the design and subsequent development of new anticancer small molecule agents. New chapters have been added to this edition on areas of particular interest and therapeutic promise, including cancer...

Beschreibung

Cancer Drug Design and Discovery, Second Edition is an important reference on the underlying principles for the design and subsequent development of new anticancer small molecule agents. New chapters have been added to this edition on areas of particular interest and therapeutic promise, including cancer genomics and personalized medicine, DNA-targeted agents and more. This book includes several sections on the basic and applied science of cancer drug discovery and features those drugs that are now approved for human use and are in the marketplace, as well as those that are still under development. By highlighting some of the general principles involved in taking molecules through basic science to clinical development, this book offers a complete and authoritative reference on the design and discovery of anticancer drugs for translational scientists and clinicians involved in cancer research.

Rezension

".offers unique information on the discovery and design of new anticancer agents, covering recent notable successes resulting from the human genome and cancer genomics projects.an excellent reference for translational researchers interested in cancer biology and medicine as well as students in pharmacy, pharmacology, or medicinal and biological chemistry." --Anticancer Research 34, 2014

Produktdetails

Einband

Gebundene Ausgabe

Erscheinungsdatum

31.10.2013

Herausgeber Stephen Neidle
Verlag Academic Press

Produktdetails

Einband

Gebundene Ausgabe

Erscheinungsdatum

31.10.2013

Herausgeber Stephen Neidle
Verlag Academic Press
Seitenzahl

640

Maße (L/B/H)

24,4/19,5/4,3 cm

Gewicht

1564 g

Auflage

2nd Revised edition

Sprache

Englisch

ISBN

978-0-12-396521-9

EU-Ansprechpartner

Kolibri 360 GmbH
Ettore-Bugatti-Straße 6-14
51149 Köln
DE
produktsicherheit@kolibri360.de

Herstelleradresse

A&C Black Publishers Ltd.
36 Soho Square
W1D 3QY London
UK
enquiries@acblack.com

Noch keine Bewertungen vorhanden

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.

Kundinnen und Kunden meinen

Bewertungen (0)

Die Leseprobe wird geladen.
  • Produktbild: Cancer Drug Design and Discovery
  • Introduction - Stephen Neidle

    Foreword - Hilary Calvert

    Part I. Basic Principles and methodology

    Modern cancer drug discovery: integrating targets, technologies and treatments - Paul Workman and
    Ian Collins

    Pharmacogenomics and personalised medicines in cancer treatment - Wei-Peng Yong, Ross Soo and
    Federico Innocenti

    Structural biology and anticancer drug design - Puja Pathuri, David Norton, Henriette Willems,
    Dominic Tisi and Harren Jhoti

    Part II. Drugs in the laboratory and clinic

    Temozolomide: from cytotoxic to molecularly-targeted agent - Malcolm Stevens

    Temozolomide: patents and the perils of invention - Malcolm Stevens

    A new generation of cell-targeted drugs for cancer treatment - Paola B. Arimondo, Nicolas Guilbaud
    and Christian Bailly

    Inhibition of DNA repair as a therapeutic target - Stephany Veuger and Nicola J Curtin
    Inhibitors of tumour angiogenesis - Adrian L. Harris and Daniele G Generali

    The Renaissance of CYP17 Inhibitors for the Treatment of Prostate Cancer - Qingzhong Hu and Rolf
    W. Hartmann

    Apoptosis in Cancer: Mechanisms, Deregulation and Therapeutic Targeting - Zahid H Siddik

    Targeting the MDM2-p53 protein-protein interaction: design, discovery and development of novel
    anticancer agents - Ian R Hardcastle

    Targeting altered metabolism - emerging cancer therapeutic strategy - Minsuh Seo, Robert Blake
    Crochet and Yong-Hwan Lee

    Inhibitors of the Phosphatidylinositol 3-kinase (PI3K) Pathway - William A Denny and Gordon W.
    Rewcastle

    Antibody-drug conjugates delivering DNA cytotoxics - John A Hartley

    Inhibition of telomerase: promise, progress and potential pitfalls - Christopher G. Tomlinson, Scott B.
    Cohen and Tracy M. Bryan

    Targeting B-RAF: the discovery and development of B-RAF inhibitors - Phillip A Harris

    Part III. The reality of cancer drugs in the clinic

    Failure Modes in Anticancer Drug Discovery and Development - Richard A. Walgren and
    Christopher. A. Slapak

    Anticancer drug registration and regulation: current challenges and possible solutions - David
    Taylor, Erling Donnelly and Silvia Chioato